{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-026060","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.852706+00:00","generated_at":"2026-05-31T10:03:41.140166+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pulse Biosciences reports Q2 prelim costs $11.7M; appoints Paul LaViolette as Co-Chairman","bullets":["GAAP costs and expenses $11.7M for Q2 2024; non-GAAP $9.4M; cash $26.2M as of June 30, excluding $60M rights offering closed July 2024.","Oversubscribed rights offering generated $60M gross proceeds; warrants could add up to $66M.","Completed first US soft tissue ablation procedure after FDA clearance; pivotal trial for benign thyroid nodules planned in 2025.","Received FDA Breakthrough Device Designation for Cardiac Surgery System for AF; first European epicardial ablations completed.","Appointed Paul LaViolette as Co-Chairman of Board; he brings 40 years medtech experience from Boston Scientific."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-026060","json":"https://secwatch.observer/filing/0001437749-24-026060.json","markdown":"https://secwatch.observer/filing/0001437749-24-026060.md","text":"https://secwatch.observer/filing/0001437749-24-026060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924026060/0001437749-24-026060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924026060/plse20240614_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:03:41.140166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0703265d95","claim":"Robert W. Duggan was appointed as Co-Chairman of the Board at PULSE BIOSCIENCES, INC..","evidence_excerpt":"the Board appointed Robert W. Duggan and Mr. LaViolette to serve as Co-Chairmen of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924026060/0001437749-24-026060-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Co-Chairman of the Board"}]},{"claim_id":"29df890726","claim":"Paul A. LaViolette was elected as Director at PULSE BIOSCIENCES, INC..","evidence_excerpt":"the Board of Directors of Pulse Biosciences, Inc. (the “Company”) elected Paul A. LaViolette to serve as a member of the Company’s Board of Directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924026060/0001437749-24-026060-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}]},{"claim_id":"6221d02184","claim":"Paul A. LaViolette was appointed as Co-Chairman of the Board at PULSE BIOSCIENCES, INC..","evidence_excerpt":"the Board appointed Robert W. Duggan and Mr. LaViolette to serve as Co-Chairmen of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924026060/0001437749-24-026060-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Co-Chairman of the Board"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}